戻る Agenda
Are current HTA processes suitable for innovative cancer medicines?
Session Chair(s)
Ron Akehurst
Emeritus Professor of Health Economics
University of Sheffield, United Kingdom
A multi-stakeholder panel will debate why current methods of value assessment are hindering optimal patient access to cancer innovations and what solutions could be adopted to evoke positive change. A multi-stakeholder panel will debate why current methods of value assessment are hindering optimal patient access to cancer innovations and what solutions could be adopted to evoke positive change.
Speaker(s)
Panel Discussion with:
Martin Price
Janssen EMEA, Pharmaceutical Companies of Johnson & Johnson, United Kingdom
Vice President, Health Economics, Market Access and Reimbursement
Panel Discussion with:
Anne-Pierre Pickaert
CARE 4 ACCESS, France
Access to Oncology Medicines Specialist; Patvocates
Panel Discussion with:
Adam Hutchings, MS
Dolon Ltd, United Kingdom
Managing Director
Panel Discussion with:
Flora Giorgio, MPHARM
European Commission, Belgium
Head of Unit Medical Devices, DG SANTE – Medical Products and Innovation